Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh çet's disease, National multicenter study of 177 cases

ConclusionAlthough IFX and ADA yields efficacy refractory BD uveitis, ADA appears to be associated with better outcome than IFX after one ‐year follow‐up.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - June 24, 2019 Category: Rheumatology Authors: Bel én Atienza‐Mateo, José Luis Martín‐Varillas, Vanesa Calvo‐Río, Rosalía Demetrio‐Pablo, Emma Beltrán, Juan Sánchez‐Bursón, Marina Mesquida, Alfredo Adan, María Victoria Hernández, Marisa Hernández‐Garfella, Elia Valls� Tags: Full Length Source Type: research